LegalizeCommission Implementing Decision (EU) 2019/1396 of 10 September 2019 laying down the rules for the application of Regulation (EU) 2017/745 of the European Parliament and of the Council as regards the designation of expert panels in the field of medical devices (Text with EEA relevance.)
Article 1
Designation of expert panels
One expert panel is designated in each of the following areas to fulfil the tasks set out in paragraphs 9 and 10 of Article 106 of Regulation (EU) 2017/745 and in paragraph 6 of Article 48 of Regulation (EU) 2017/746:
- (1) Orthopaedics, traumatology, rehabilitation, rheumatology;
- (2) Circulatory system;
- (3) Neurology;
- (4) Respiratory system, anaesthesiology, intensive care;
- (5) Endocrinology and diabetes;
- (6) General and plastic surgery and dentistry;
- (7) Obstetrics and gynaecology, including reproductive medicine;
- (8) Gastroenterology and hepatology;
- (9) Nephrology and urology;
- (10) Ophthalmology;
- (11) In vitro diagnostic medical devices (IVD);
- (12) Paediatrics and rare diseases.
An additional expert panel is designated to be in charge of the decision referred to in point (c) of Section 5.1 of Annex IX to Regulation (EU) 2017/745.
Article 2
Appointment of advisors and establishment of the central list
For the purpose of Article 106(5) of Regulation (EU) 2017/745, advisors shall be appointed to the expert panels following a call for expression of interest and consultation with the Medical Device Coordination Group (‘MDCG’), based on selection criteria stipulated in that call for expression of interest.
The number of members of each expert panel shall be determined in the call for expression of interest referred to in paragraph 1.
For the purpose of Article 106(6) of Regulation (EU) 2017/745 and following consultation with the MDCG, advisors who satisfy the criteria stipulated in the call but who are not appointed to an expert panel shall be included in a central list of available experts (the ‘central list’).
Advisors shall be selected with regard to the need to ensure:
- (a) adequate and up-to-date clinical, scientific or technical expertise in the areas referred to in Article 1(1);
- (b) independence, impartiality, objectivity and absence of conflict of interest as outlined in Article 107 of Regulation (EU) 2017/745;
- (c) balanced geographical representation.
Where it is necessary due to the workload of a certain expert panel or the need to provide the required expertise to a certain expert panel, additional advisors may be appointed to that expert panel from the central list.
Where it is necessary due to the workload of a certain expert panel or the need to provide the required expertise to a certain expert panel, advisors on the central list or in another expert panel may be assigned to that expert panel for a specific role or task and for a limited period of time.
The central list may be updated by launching subsequent calls for expression of interest.
Article 3
Sub-groups
An expert panel may, in agreement with the Secretariat referred to in Article 10, establish permanent or ad hoc sub-groups entrusted with specific tasks and composed of a certain number of its members.
Sub-groups shall operate in accordance with the common rules of procedure for the expert panels, referred to in Article 9(1).
Article 4
Term of office
Advisors shall be appointed as members of an expert panel for a term of three years, with the possibility of renewal.
Where an advisor no longer complies with the conditions set out in Articles 12 and 15 or in Article 339 of the Treaty on the Functioning of the European Union, resigns or is no longer capable of contributing effectively to the expert panel's work, the Commission may dismiss that advisor.
Where an advisor is dismissed during his or her term of office, a replacement for that advisor shall be appointed for the remainder of the term from the central list.
Article 5
Election of the Chair and Vice-Chair
At the beginning of each term of office referred to in Article 4, each panel and its sub-groups shall, acting by simple majority, elect a Chair and a Vice-Chair from among its members.
The term of office of the Chair and Vice-Chair shall be three years, and shall be renewable. Any replacement of the Chair or Vice-Chair during that term of office shall take place according to the procedure referred to in paragraph 1 and shall be valid for the remainder of the term.
As regards sub-groups, the term of office of the Chair and Vice-Chair shall run from the moment of their election until the expiration of the mandate of the sub-group.
Article 6
Voting rules
When adopting scientific opinions or views, as applicable, in the context of Articles 54(1) and 61(2) of Regulation (EU) 2017/745 and Article 48(6) of Regulation (EU) 2017/746, the expert panel shall make decisions in accordance with Article 106(12) of Regulation (EU) 2017/745.
Article 7
Coordination committee
A coordination committee (the ‘Committee’) composed of the Chairs and Vice-Chairs of all expert panels shall be established following the election referred to in Article 5.
The Committee shall, inter alia:
- — ensure effective exchange of information between expert panels;
- — adopt and review the common rules of procedure for the expert panels in accordance with Article 9;
- — adopt and review internal guidance and methodologies to be used by the expert panels.
The Committee shall operate in accordance with the common rules of procedure referred to in Article 9(1).
Article 8
Preparation of opinions, views or advice
For each opinion, view or advice under preparation, the Chair of the expert panel or of the sub-group may appoint a rapporteur, a co-rapporteur and reviewers.
The expert panels shall follow the common rules of procedure referred to in Article 9 and any relevant guidance adopted by the Committee as referred to in Article 7(2) third indent.
In the context of the activities of expert panels referred to in Article 54(1) of Regulation (EU) 2017/745, the expert panels shall use the guidance to be provided by the Commission as set out in point (h) of Section 5.1 of Annex IX to Regulation (EU) 2017/745.
Article 9
Common rules of procedure
On a proposal by the Secretariat referred to in Article 10 and in agreement with the Commission services, the Committee shall adopt common rules of procedure for all expert panels by simple majority of its members.
The Chairs shall consult their respective expert panels on the content of the common rules of procedure prior to adoption.
The common rules of procedure for the expert panels shall provide for, inter alia:
- (a) procedures for carrying out the tasks of the expert panels as referred to in paragraphs 9 and 10 of Article 106 of Regulation (EU) 2017/745;
- (b) rules ensuring the application of the principles laid down in Articles 12 to 15.
The Committee shall, in agreement with the Secretariat referred to in Article 10 and the Commission services, update the common rules of procedure when needed.
The common rules of procedure shall be publicly available on a dedicated website.
Article 10
Secretariat
The European Medicines Agency, acting as secretariat for the expert panels in accordance with Article 30 of Regulation (EU) 2022/123 of the European Parliament and of the Council ([^E0001]), shall also provide the secretariat for the Committee referred to in Article 7 of this Decision (the ‘Secretariat’).
Article 11
Remuneration
Advisors shall be remunerated for their preparatory work and participation (in person or by electronic means) in the meetings of the expert panel and in other activities of the expert panels governed by this Decision. The remuneration shall be established according to the criteria set out in the Annex.
Travel and, where appropriate, subsistence expenses of advisors in connection with the activities of the expert panels governed by this Decision shall be reimbursed by the Secretariat in accordance with the provisions in force at the European Medicines Agency. Those expenses shall be reimbursed within the limits of the available appropriations allocated to the European Medicines Agency under the annual procedure for the allocation of resources.
Article 12
Independence, impartiality and objectivity
Advisors shall be appointed or assigned in their personal capacity. They shall not delegate their responsibilities to any other person.
Advisors shall not have financial or other interests in the medical device industry or in a notified body or any other organisation or sector, which could affect their independence, impartiality and objectivity. They shall make a declaration of interests indicating any interest which may compromise or may reasonably be perceived to compromise their independence, impartiality and objectivity, including any relevant circumstances relating to their close family members.
Declarations of interests shall be submitted in writing, when applying to the call for expression of interest.
Advisors shall update their declarations of interest:
- — prior to the appointment to an expert panel or prior to inclusion on the central list;
- — whenever a change of circumstances so requires;
- — prior to commencement of a specific task in the expert panel.
Where the obligations referred to in paragraphs 1 to 4 are not met, the Commission or the Secretariat may take all appropriate measures.
Article 13
Commitment
Advisors shall commit to acting in the public interest and observing the principles listed in Articles 12 to 15. For that purpose, they shall sign a declaration of commitment.
Advisors shall respond to requests and other communications from the Chair of their respective expert panel or sub-group and from the Secretariat. They shall dedicate the necessary effort to complete the assigned tasks to the best of their ability and within the timelines as described in the common rules of procedure referred to in Article 9.
Article 14
Transparency
The activities of the expert panels shall be carried out in a transparent manner. The Secretariat shall, in particular, make the following information available to the public on a dedicated website:
- (a) the names of the advisors appointed or assigned to the expert panels or included in the central list of available experts;
- (b) the curriculum vitae and the declarations of interests, confidentiality and commitment of advisors appointed or assigned to the expert panels;
- (c) the common rules of procedure of the expert panels referred to in Article 9;
- (d) opinions, views and advice in accordance with Article 8.
Article 15
Confidentiality
Advisors shall not divulge any information of confidential nature acquired as part of their work in the expert panels or as a result of other activities governed by this Decision. For that purpose, they shall sign a declaration of confidentiality.
Advisors shall comply with the rules on security regarding the protection of Union classified information and sensitive non-classified information, laid down in Decisions (EU, Euratom) 2015/443 and (EU, Euratom) 2015/444.
Where the obligations referred to in paragraphs 1 and 2 are not met, the Commission or the Secretariat may take all appropriate measures.
Article 16
Entry into force and date of application
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
ANNEX
REMUNERATION OF ADVISORS
- 1.The remuneration of advisors is 450 EUR for each full working day.
- 2.The total working time is calculated and rounded to the nearest half working day.
- 3.For tasks referred to in Article 54(1) of Regulation (EU) 2017/745 and Article 48(6) of Regulation (EU) 2017/746, the maximum number of working days for which experts may be remunerated is set out in Table 1.
Table 1
Maximum number of working days for which experts may be remunerated for tasks referred to in Article 54(1) of Regulation (EU) 2017/745 and Article 48(6) of Regulation (EU) 2017/746
| Regulation (EU) 2017/745 Article 54(1) | Regulation (EU) 2017/745 Article 54(1) | Regulation (EU) 2017/746 Article 48(6) | |
|---|---|---|---|
| Decision on whether a scientific opinion should be developed (Yes/No) | Development and provision of a scientific opinion | Provision of a view of the performance of an in vitro diagnostic medical device | |
| Chair/Vice-Chair | N/A | 3 | 3 |
| Rapporteur | 1 | 5 | 5 |
| Co-rapporteur | 1 | 5 | 5 |
| Reviewer | N/A | 1 | 1 |
| Advisor assigned for a specific task | N/A | 1 | 1 |
- 4.For tasks referred to in Articles 55(3), 61(2), 106(10)(a) to (f) and 106(11) of Regulation (EU) 2017/745 and Article 50(3) of Regulation (EU) 2017/746, divided into categories depending on their level of complexity, the maximum number of working days is specified in Table 2.
Table 2
Maximum number of working days for which experts may be remunerated for tasks under Article 55(3), Article 61(2), Article 106(10), points (a) to (f), and Article 106(11) of Regulation (EU) 2017/745 and Article 50(3) of Regulation (EU) 2017/746
| Complexity of task (indicative criteria [^E0002]) | Acting as | Remuneration in in full-day equivalents |
|---|---|---|
| Category I — opinion based on examination of a low volume of data, documents and literature — no consultation of other scientific bodies — no information available from stakeholders including patient organisations and healthcare professionals — indicatively, less than three months to accomplish task | Chair/Vice-Chair | 2 |
| Category I — opinion based on examination of a low volume of data, documents and literature — no consultation of other scientific bodies — no information available from stakeholders including patient organisations and healthcare professionals — indicatively, less than three months to accomplish task | Rapporteur | 3 |
| Category I — opinion based on examination of a low volume of data, documents and literature — no consultation of other scientific bodies — no information available from stakeholders including patient organisations and healthcare professionals — indicatively, less than three months to accomplish task | Co-rapporteur | 3 |
| Category I — opinion based on examination of a low volume of data, documents and literature — no consultation of other scientific bodies — no information available from stakeholders including patient organisations and healthcare professionals — indicatively, less than three months to accomplish task | Reviewer | 0,5 |
| Category I — opinion based on examination of a low volume of data, documents and literature — no consultation of other scientific bodies — no information available from stakeholders including patient organisations and healthcare professionals — indicatively, less than three months to accomplish task | Advisor assigned for a specific task | 0,5 |
| Category II — opinion based on a significant volume of data, documents and literature — feedback following consultation, if any, of other scientific bodies to be examined — information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, three to six months to accomplish task | Chair/Vice-Chair | 3 |
| Category II — opinion based on a significant volume of data, documents and literature — feedback following consultation, if any, of other scientific bodies to be examined — information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, three to six months to accomplish task | Rapporteur | 5 |
| Category II — opinion based on a significant volume of data, documents and literature — feedback following consultation, if any, of other scientific bodies to be examined — information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, three to six months to accomplish task | Co-rapporteur | 5 |
| Category II — opinion based on a significant volume of data, documents and literature — feedback following consultation, if any, of other scientific bodies to be examined — information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, three to six months to accomplish task | Reviewer | 1 |
| Category II — opinion based on a significant volume of data, documents and literature — feedback following consultation, if any, of other scientific bodies to be examined — information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, three to six months to accomplish task | Advisor assigned for a specific task | 1 |
| Category III — opinion based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than six months to accomplish task | Chair/Vice-Chair | 4 |
| Category III — opinion based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than six months to accomplish task | Rapporteur | 7 |
| Category III — opinion based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than six months to accomplish task | Co-rapporteur | 7 |
| Category III — opinion based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than six months to accomplish task | Reviewer | 2 |
| Category III — opinion based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than six months to accomplish task | Advisor assigned for a specific task | 2 |
| Category IV — contributions based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than 12 months to accomplish task | Chair/Vice-Chair | 8 |
| Category IV — contributions based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than 12 months to accomplish task | Rapporteur | 21 |
| Category IV — contributions based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than 12 months to accomplish task | Co-rapporteur | 21 |
| Category IV — contributions based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than 12 months to accomplish task | Reviewer | 4 |
| Category IV — contributions based on a significant volume of data, documents and literature — high volume of feedback following consultation, if any, of other scientific bodies to be examined — large amount of information available from stakeholders including patient organisations and healthcare professionals, to be examined — indicatively, more than 12 months to accomplish task | Advisor assigned for a specific task | 4 |
Each of these criteria may be applied independently
- 5.The remuneration shall be conditional on the completion of the relevant tasks as per the common rules of procedure.
[^E0001]: Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (OJ L 20, 31.1.2022, p. 1, ELI: http://data.europa.eu/eli/reg/2022/123/oj).
Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.
This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence.
EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.